Pfizer (NYSE:PFE) Stock Price Up 0.3%

Pfizer Inc. (NYSE:PFE) shares were up 0.3% during mid-day trading on Friday . The stock traded as high as $25.49 and last traded at $25.34. Approximately 10,662,850 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 41,551,375 shares. The stock had previously closed at $25.26.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on PFE shares. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Trading Up 0.5 %

The stock has a market cap of $143.72 billion, a P/E ratio of 70.39, a PEG ratio of 1.18 and a beta of 0.61. The stock’s fifty day moving average price is $27.01 and its 200 day moving average price is $28.48. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.14 earnings per share. Equities research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.62%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 466.67%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. SlateStone Wealth LLC lifted its holdings in Pfizer by 6.8% during the first quarter. SlateStone Wealth LLC now owns 8,224 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 522 shares in the last quarter. Bond & Devick Financial Network Inc. boosted its position in shares of Pfizer by 22.6% during the first quarter. Bond & Devick Financial Network Inc. now owns 12,479 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 2,300 shares during the last quarter. Clear Creek Financial Management LLC lifted its stake in Pfizer by 16.8% in the 1st quarter. Clear Creek Financial Management LLC now owns 40,723 shares of the biopharmaceutical company’s stock worth $1,134,000 after purchasing an additional 5,851 shares in the last quarter. Mesirow Financial Investment Management Inc. bought a new position in Pfizer during the first quarter valued at approximately $10,904,000. Finally, Carr Financial Group Corp increased its position in Pfizer by 173.6% in the first quarter. Carr Financial Group Corp now owns 23,585 shares of the biopharmaceutical company’s stock worth $654,000 after purchasing an additional 14,966 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.